Table 1.
Group differences in demographic and clinical variables between remitters and non-remitters.
| Non-Remitters (N = 22) |
Remitters (N = 24) |
Group Comparison | |
|---|---|---|---|
| Age (median, IQR) | 64.5 (8.0) | 66.0 (11.5) | p = 0.574 |
| Race (CC/AA) | 18/4 | 20/4 | p = 1.000 |
| Gender (female) | 11 | 18 | p = 0.126 |
| Education (median, IQR) | 16.0 (2.0) | 13.0 (6.0) | p = 0.269 |
| MMSE (median, IQR) | 29.0 (1.8)c | 29.0 (2.0) | p = 0.857 |
| CIRSG Total (median, IQR) | 8.0 (4.8)e | 9.0 (4.3)c | p = 0.918 |
| CIRSG Vascular Item (median, IQR) | 2.0 (2.0) | 2.0 (2.0) | p = 0.818 |
| Depression Onset Age (median, IQR) | 30 (32)a | 43 (39.3)c | p = 0.563 |
| Years lived with depression (median, IQR) | 31.0 (32.3)a | 25.0 (42.3)c | p = 0.772 |
| Depression Type (single/recurrent) | 11/9 | 7/16a | p = 0.130 |
| MADRS Baseline (median, IQR) | 27.0 (7) | 23.5 (11) | p = 0.069 |
| MADRS 1 Week (median, IQR) | 24.5 (7) | 19.5 (10.5) | p = 0.034* |
| MADRS End (median, IQR) | 20.0 (8.5)a | 3 (6) | p < 0.001* |
| MADRS Change Ratio (median, IQR)(%) | 32.3 (33.0)a | 87.5 (26.2) | p <0.001* |
| Venlafaxine Level 1st Dose (median, IQR)(ng/ml) | 26.0 (14.4)e | 21.0 (13.5)d | p = 0.185 |
| Venlafaxine Level 1 Week (median, IQR)(ng/ml) | 102.5 (103)b | 75.0 (23.9)a | p = 0.381 |
| Venlafaxine Level End (median, IQR)(ng/ml) | 270.0 (355.8)b | 107.5 (138)b | p = 0.003* |
| CBF Baseline (median, IQR) | 43.3 (19.1) | 46.5 (13.7) | p = 0.429 |
| CBF Change (median, IQR) | 2.8 (12.9) | 0.3 (15.8) | p = 0.403 |
*
Significant (p < 0.05) differences;
a
One,
b
Two,
c
Three,
d
Four, or
e
Five participant’s data was missing;
Abbreviations: IQR, interquartile range; CC, Caucasian; AA, African American; MMSE, mini-mental state examination; CIRSG, cumulative illness rating scale for geriatrics; MADRS, Montgomery–Åsberg Depression Rating Scale; the group comparisons of race, gender, and depression type were conducted with Fisher’s exact test, while others with Mann-Whitney U test.